Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
 
Sign in
Join now
featured
Published in COVID-19 and
1 other channel

Expert Opinion / Commentary · May 05, 2020

Remdesivir for COVID-19

Jonathan Temte MD, PhD

 

 Save  Recommend
 Share

Additional Info

  1. Grein J, Ohmagari N, Shin D, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. NEJM. Published on April 10, 2020. DOI: 10.1056/NEJMoa2007016
  2. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet. Published Online on April 29, 2020.
  3. Adaptive COVID-19 Treatment Trial (ACTT). National Library of Medicine. ClinicalTrials.gov. Accessed 5/05/2020.

Disclosure statements are available on the authors' profiles:

Jonathan Temte MD, PhD

Further Reading

Most Read This Week

Recently Updated